FDA approves generic versions of Novartis’ top multiple sclerosis drug

Organisation: Position: Deadline Date: Location:

The US Food and Drug Administration has approved three generic versions of Swiss drugmaker Novartis’ top-selling multiple sclerosis (MS) medicine Gilenya, reports Reuters Health. The approval allows HEC Pharm Co Ltd, Biocon Ltd and Sun Pharmaceutical Industries Ltd to produce the drug for the treatment of relapsing forms of MS in adult patients.

The report says the Novartis was defending patents on Gilenya in the US to block generic rivals. Earlier in June, US federal court order had prevented rival generic makers from selling versions of Gilenya in the US.

Reuters Health report

Receive Medical Brief's free weekly e-newsletter

Related Posts

Thank you for subscribing to MedicalBrief

MedicalBrief is Africa’s premier medical news and research weekly newsletter. MedicalBrief is published every Thursday and delivered free of charge by email to over 33 000 health professionals.

Please consider completing the form below. The information you supply is optional and will only be used to compile a demographic profile of our subscribers. Your personal details will never be shared with a third party.

Thank you for taking the time to complete the form.